# Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

> **NCT04946370** · PHASE1,PHASE2 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 52 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 225Ac-J591
- **DRUG:** Pembrolizumab
- **DRUG:** Androgen receptor inhibitor
- **DIAGNOSTIC_TEST:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT04946370
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-12
- **Primary completion:** 2027-10
- **Final completion:** 2029-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- United States Department of Defense
- Merck Sharp & Dohme LLC

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946370, "Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04946370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*